Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2025
Lyvdelzi (seladelpar) receives Health Canada approval for the treatment of primary biliary cholangitis
21 October 2025 - Gilead Sciences today announced that Health Canada has approved Lyvdelzi (seladelpar) for the treatment of primary biliary ...
Posted by Michael Wonder on 22 Oct 2025
Pfizer Canada announces Health Canada approval of Abrysvo for adults 18+
21 October 2025 - With the approval of Arbysvo for adults aged 18+, there is now a way to help ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 16 Oct 2025
Incyte Canada announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis in children ages 2-11
15 October 2025 - First and only topical JAK inhibitor cream approved in Canada for paediatric atopic dermatitis. ...
Posted by Michael Wonder on 08 Oct 2025
Ontario connecting patients to life-saving cancer drugs faster
7 October 2025 - The Ontario Government is leading the world in cancer care by launching the Funding Accelerated for ...
Posted by Michael Wonder on 07 Oct 2025
Jesse's dad, who walked Canada for his son, cheers approval of new Duchenne drug
3 October 2025 - Vamorolone is the first Health Canada approved drug developed specifically to treat Duchenne. ...
Posted by Michael Wonder on 03 Oct 2025
Health Canada approves Agamree (vamorolone) as the first treatment for Duchenne muscular dystrophy in Canada
2 October 2025 - Kye Pharmaceuticals announced today that Health Canada has approved Agamree (vamorolone) for the treatment of Duchenne muscular ...
Posted by Michael Wonder on 02 Oct 2025
Organon Canada announces the availability of Nduvra (1% tapinarof cream) for the topical treatment of plaque psoriasis in adults
1 October 2025 - Organon Canada announces the availability of Ndruvra (1% tapinarof cream) for the topical treatment of plaque psoriasis ...
Posted by Michael Wonder on 24 Sep 2025
New subcutaneous formulation of Opdivo receives positive INESSS recommendation for multiple tumour types
23 September 2025 - Milestone decision recognises the value of SC formulation of Opdivo to help support delivery flexibility ...
Posted by Michael Wonder on 24 Sep 2025
Teva and Medincell’s risperidone LAI approved in Canada as Longavo
23 September 2025 - Teva Canada has received regulatory approval for risperidone long-acting injection from Health Canada for the treatment ...
Posted by Michael Wonder on 21 Sep 2025
Moderna produces its first Canadian mRNA vaccines in its new state of the art Quebec facility
19 September 2025 - Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for ...
Posted by Michael Wonder on 20 Sep 2025
Health Canada approves Celltrion’s Stoboclo and Osenvelt (CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia and Xgeva, respectively
18 September 2025 - The approval is based on the totality of evidence including results from a Phase III clinical ...
Posted by Michael Wonder on 19 Sep 2025
Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases
18 September 2025 - -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 16 Sep 2025
AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta
15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...